Why did the AnteoTech (ASX:ADO) share price tumble 13% on Monday

AnteoTech shares have suffered in the past week.

| More on:
man grimaces next to falling stock graph

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key Points

  • AnteoTech shares fall again on the back of a quarterly business update
  • Management noted high barriers to market entry
  • Company still in collaboration with TGA regarding regulatory approval for its RDT

The AnteoTech Ltd (ASX: ADO) share price tumbled today following the release of a business update from the company.

At market close, the nanotechnology company's shares finished down 13.33% to 19.5 cents.

Ever since AnteoTech's announcement last week regarding its EuGeni Reader and COVID-19 Rapid Diagnostic Test (RDT), its shares have dropped by 45%.

AnteoTech signals challenging market entry

Investors have continued to sell off AnteoTech shares after digesting the company's business update for the second quarter of FY22.

According to the release, AnteoTech advised that its engagement with the Therapeutic Goods Administration (TGA) is ongoing. The company is hoping to achieve regulatory approval for its EuGeni Reader and COVID-19 RDT.

Management noted that governments worldwide are continuing to heavily regulate in-vitro diagnostic (IVD) devices for market entry.

The products must be supported by the manufacturer and integrate the support of OEM suppliers, distributors and supply chain organisations. While many companies close to AnteoTech have failed to adhere to the stringent guidelines, this has forced them to remove product batches or entire products from the market.

For AnteoTech, being associated with these companies has caused valuable reputational damage and is hindering further developments.

At the Annual General Meeting in November, CEO Derek Thomson presented the CY22 Revenue Generation Approach, outlining the four key areas of focus. These areas were increasing market footprint, regulatory approvals, building reputation, and maximising revenues.

The business team is expected to drive sales and marketing processes to sell to target segments. This will be executed by utilising the company's global distribution network.

Looking at a financial standpoint, AnteoTech advised that cash receipts for the quarter totalled $2.13 million. This primarily came from a $1.96 million refund under the Federal Government's Research & Development (R&D) tax incentive scheme.

Net cash outflows from operating activities stood at $0.61 million.

The Company stated it remains well-funded to support its near-term commercial and clinical milestones.

At the end of the calendar year, AnteoTech had $16.62 million cash on hand and no debt.

About the AnteoTech share price

Despite today's heavy losses, the AnteoTech share price has advanced by 95% over the past 12 months.

The company's shares reached an 8-month high of 41.5 cents on 24 January, before crashing back down.

Based on today's closing price, AnteoTech has a market capitalisation of roughly $384.94 million, with more than 1.97 billion shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Market News

Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

'Trading at a discount': Why now is the time to buy CSL shares

This investing expert says CSL shares now represent an appealing buying opportunity.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Here's what could impact CSL shares from the biotech's AGM

The biotech giant's leadership had plenty to say.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why this fundie is backing ResMed shares in FY25

There's plenty more upside, this fund says.

Read more »